Business
GC Biopharma's Varicella Vaccine Strain 'MAV/06' Listed in WHO Position Paper
GC Biopharma (006280.KS), a global biopharmaceutical company, today announced that its proprietary varicella vaccine strain MAV/06 has been included in the World Health Organization (WHO) Position Paper on varicella vaccination, published on November 21.
About this update from Gc Biopharma Corp.
[{"type":"list","items":[{"val":[{"type":"text","content":"Officially recognized by WHO as a standard varicella vaccine strain alongside Oka","length":86,"tagName":"p"}]},{"val":[{"type":"text","content":"Interchangeability endorsed, enhancing global supply security","length":66,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":152,"olType":false},{"type":"text","content":"YONGIN, South Korea, Dec. 2, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a global biopharmaceutical company, today announced that its proprietary varicella vaccine strain MAV/06 has been included in the World Health Organization (WHO) Position Paper on varicella vaccination, published on November 21.","length":309,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/GC Biopharma)","displaySize":"","headline":null,"caption":"(PRNewsfoto/GC Biopharma)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":400,"url":"https://media.zenfs.com/en/prnewswire.com/4b834899abdf3d99fcde8560d438cc9a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/B0c2J77qVeMlBCJvcjoKKg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwNTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/4b834899abdf3d99fcde8560d438cc9a","width":400,"height":400}},"href":"https://mma.prnewswire.com/media/1888566/GC_Biopharma_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"WHO Position Paper serves as the most authoritative global guidance for immunization policy, developed by the Strategic Advisory Group of Experts on Immunization (SAGE).","length":169,"tagName":"p"},{"type":"text","content":"With this inclusion, BARYCELA Inj. — GC Biopharma's varicella vaccine based on the MAV/06 strain — has attained equivalent international recognition to Oka strain-based vaccines. The WHO also endorsed the interchangeability of MAV/06 and Oka strains, allowing BARYCELA Inj. to be vaccinated with existing varicella vaccines in two-dose immunization schedules. This positions BARYCELA Inj. as a validated alternative in the global varicella vaccine market.","length":464,"tagName":"p"},{"type":"text","content":"The immunogenicity and safety of MAV/06 were confirmed in a Phase 3 clinical trial of BARYCELA Inj., published in a peer-reviewed journal. The study demonstrated strong immune responses and a favorable safety profile, supporting its use in national immuniz...